Award Category: Education & Communications

The world’s first point-and-click skin cancer detection device for
Primary Care Providers. We equip America’s most common provider to
detect the most common cancer. Our CE-marked, FDA Breakthrough product
is a handheld device that employs patented optical spectroscopy and
machine learning technologies to effectively detect all common skin
cancers.

Shockwave’s first-of-its-kind Coronary Intravascular Lithotripsy (IVL)
treats patients with severely calcified coronary artery disease (CAD) by
cracking calcium in the heart to restore blood flow. The technology is a
novel application of kidney stone lithotripsy that has been
reverse-engineered to make it safe and effective for use in the heart.

The system adopts real-time ultrasound imaging navigation, human-machine
interface techniques, and closed-loop algorithms to optimize the RFA
process. It reduces the size of wound on patients, operation duration,
and recovery time. iRFA’s precision tumor targeting and ablation
completion are comparable to clinical requirements.

CTSAS is the first surgical navigation system using the dodecahedral
tracker which provides maximum viewing angles with a greatly reduced
size. Combined with real-time visualization and navigation corrections
of patient’s anatomy, the system can track each vertebra with improved
accuracy, especially in the procedure of multilevel spinal surgeries.

Our tests identify genetic factors that contribute to the efficacy,
safety, and tolerability of commonly prescribed medicines. We help
clinicians optimize drug treatment by determining the patient’s expected
outcome, in turn reducing failed drug trials and adverse drug reactions,
thereby decreasing time to achieving optimal therapeutic response.

“The Galleri test detects a shared cancer signal across 50+ types of
cancer with a single blood draw.This groundbreaking technology finds
more cancers at earlier stages—even before symptoms appear and when
treatment is more likely to be successful. This could help prevent ~39%
of cancer deaths that would otherwise occur in the next 5 years.”

The Recursion OS harnesses multiple breakthrough technologies, including
machine learning, to create, organize and study vast amounts of
biological data to build Maps of Biology that can predict trillions of
relationships across biology and chemistry to discover novel insights.

NuraLogix created the world’s first, most comprehensive, contactless
blood pressure and wellness monitoring solution. It is powered by the
company’s patented Transdermal Optical Imaging (TOI™) technology, which
extracts facial blood flow patterns and combines info with powerful AI
data models developed from more than 40,000 patients with multiple
health conditions.